BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28592767)

  • 1. [Immune checkpoint inhibitors and allogeneic hematopoietic stem cell transplantation].
    Kondo E; Maeda Y
    Rinsho Ketsueki; 2017; 58(5):506-513. PubMed ID: 28592767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
    Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome.
    Khaddour K; Musiek A; Cornelius LA; Dehdashti F; Westervelt P; Fields R; Ansstas G
    J Immunother Cancer; 2019 Dec; 7(1):338. PubMed ID: 31801591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
    Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
    Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation.
    Köhler N; Ruess DA; Kesselring R; Zeiser R
    Front Immunol; 2021; 12():634435. PubMed ID: 33746972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
    Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
    Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
    Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-programmed cell death-1 monoclonal antibody therapy before or after allogeneic hematopoietic cell transplantation for classic Hodgkin lymphoma: a literature review.
    Ito A; Kim SW; Fukuda T
    Int J Hematol; 2022 Sep; 116(3):309-314. PubMed ID: 35653054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review.
    Bobillo S; Nieto JC; Barba P
    Bone Marrow Transplant; 2021 Aug; 56(8):1784-1793. PubMed ID: 33742152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation.
    Soiffer RJ
    Bone Marrow Transplant; 2019 Aug; 54(Suppl 2):798-802. PubMed ID: 31431704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation.
    Fuji S; Ohmoto A
    Expert Rev Hematol; 2022 Jan; 15(1):45-51. PubMed ID: 35086410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular-targeted therapy and its impact on post-transplant immunity].
    Kato K
    Rinsho Ketsueki; 2018; 59(5):557-565. PubMed ID: 29877247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
    Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
    Tsirigotis P; Shimoni A; Nagler A
    Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hematopoietic stem cell transplantation in the era of new molecular-targeted therapies].
    Kato K
    Rinsho Ketsueki; 2018; 59(10):2334-2342. PubMed ID: 30305543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
    Sinkovics JG
    Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
    Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
    J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
    Hashimoto D; Merad M
    Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.